Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Mixed testimony on kratom bill as health officials and advocates disagree on product limits
Summary
At a packed hearing, witnesses for and against SB463—proposed regulation requiring registration and labeling for kratom products—testified on health uncertainties, market safety and the need for state rules in the absence of federal regulation.
The Senate Health and Human Services committee and the Committee on CPN heard SB463, a bill proposing registration and labeling requirements for kratom products, including potency limits and restrictions on certain drug‑interaction formulations. The Department of Health testified in opposition, saying the agency lacks sufficient evidence to set safe levels and that a regulatory program would be premature.
Why it matters: Kratom is an herbal product with a range of reported uses and concerns. Proponents of regulation, including the American Kratom…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
